Shopping Cart 0
Cart Subtotal
AED 0

ImmunoGen Inc (IMGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

ImmunoGen Inc (ImmunoGen) is a clinical-stage biotechnology company that focuses on the development of antibody-drug conjugate therapies for the treatment of cancer. The company's lead product candidate, mirvetuximab soravtansine, a folate receptor alpha (FRa) intended for the treatment of platinum-resistant ovarian cancer and other types of solid tumors, and in Phase 1b/2 testing in combination regimens. Its other pipeline products include IMGN779, a CD33-targeting product candidate for acute myeloid leukemia (AML); and IMGN632 for AML, B-cell acute lymphocytic leukemia, myelodysplastic syndrome and other CD123-positive malignancies. It also carries out early state programs in the areas of solid and liquid tumors. The company has partnership with various pharmaceutical companies to develop and commercialize anticancer compounds. ImmunoGen is headquartered in Waltham, Massachusetts, the US.

ImmunoGen Inc (IMGN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ImmunoGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

ImmunoGen Inc, Medical Devices Deals, 2012 to YTD 2018 10

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 12

ImmunoGen Enters into Research Agreement with Merck 13

Ventana Medical Systems Enters into Co-Development Agreement with ImmunoGen 14

CytomX Therapeutics Enters Into Co-Development Agreement With ImmunoGen fOR Probody-Drug Conjugates Therapies 15

Licensing Agreements 17

Takeda Enters into Licensing Agreement with ImmunoGen 17

CytomX Therapeutics Exercises Option for Licensing Agreement with ImmunoGen 18

ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 19

Equity Offering 20

ImmunoGen Raises USD150.7 Million in Public Offering of Shares 20

ImmunoGen Raises USD108.4 Million in Public Offering of Shares 22

ImmunoGen Plans to Raise up to USD50 Million in Public Offering 24

ImmunoGen Completes Public Offering Of Common Stock For USD 100 Million 25

Debt Offering 27

ImmunoGen Raises USD100 Million in Private Placement of 4.5% Notes Due 2021 27

Asset Transactions 28

Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 28

TPG Special Situations Partner to Acquire Kadcyla Royalty Rights from ImmunoGen for USD200 Million 29

ImmunoGen Inc-Key Competitors 30

ImmunoGen Inc-Key Employees 31

ImmunoGen Inc-Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 33

Financial Announcements 33

Nov 02, 2018: ImmunoGen reports recent progress and third quarter 2018 operating results 33

Jul 27, 2018: ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results 35

May 04, 2018: ImmunoGen Reports Recent Progress and First Quarter 2018 Operating Results 37

Feb 09, 2018: ImmunoGen Reports Pipeline Progress and 2017 Operating Results 39

Nov 03, 2017: ImmunoGen Reports Recent Progress and Third Quarter 2017 Operating Results 41

Jul 28, 2017: ImmunoGen Reports Recent Progress and Second Quarter 2017 Operating Results 43

May 05, 2017: ImmunoGen Reports Recent Progress and First Quarter 2017 Operating Results 45

Feb 17, 2017: ImmunoGen Reports Recent Progress and Operating Results for Six-Month Period and Quarter Ended December 31, 2016 47

Corporate Communications 49

Apr 25, 2018: ImmunoGen Appoints Blaine McKee as Executive Vice President and Chief Business Officer 49

Jan 23, 2017: ImmunoGen Announces Departure of Sandra Poole 50

Product News 51

03/14/2018: ImmunoGen Announces Presentations at AACR Annual Meeting Highlighting Continued Innovation in ADCs 51

Appendix 52

Methodology 52

About GlobalData 52

Contact Us 52

Disclaimer 52


List Of Figure

List of Figures

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

ImmunoGen Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

ImmunoGen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ImmunoGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ImmunoGen Inc, Deals By Therapy Area, 2012 to YTD 2018 9

ImmunoGen Inc, Medical Devices Deals, 2012 to YTD 2018 10

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 12

ImmunoGen Enters into Research Agreement with Merck 13

Ventana Medical Systems Enters into Co-Development Agreement with ImmunoGen 14

CytomX Therapeutics Enters Into Co-Development Agreement With ImmunoGen fOR Probody-Drug Conjugates Therapies 15

Takeda Enters into Licensing Agreement with ImmunoGen 17

CytomX Therapeutics Exercises Option for Licensing Agreement with ImmunoGen 18

ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 19

ImmunoGen Raises USD150.7 Million in Public Offering of Shares 20

ImmunoGen Raises USD108.4 Million in Public Offering of Shares 22

ImmunoGen Plans to Raise up to USD50 Million in Public Offering 24

ImmunoGen Completes Public Offering Of Common Stock For USD 100 Million 25

ImmunoGen Raises USD100 Million in Private Placement of 4.5% Notes Due 2021 27

Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 28

TPG Special Situations Partner to Acquire Kadcyla Royalty Rights from ImmunoGen for USD200 Million 29

ImmunoGen Inc, Key Competitors 30

ImmunoGen Inc, Key Employees 31

ImmunoGen Inc, Subsidiaries 32

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

ImmunoGen Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

ImmunoGen Inc (ImmunoGen) is a clinical-stage biotechnology company that focuses on the development of antibody-drug conjugate therapies for the treatment of cancer. The company's lead product candidate, mirvetuximab soravtansine, a folate receptor alpha (FRa) intended for the treatment of platinum-resistant ovarian cancer and other types of solid tumors, and in Phase 1b/2 testing in combination regimens. Its other pipeline products include IMGN779, a CD33-targeting product candidate for acute myeloid leukemia (AML); and IMGN632 for AML, B-cell acute lymphocytic leukemia, myelodysplastic syndrome and other CD123-positive malignancies. It also carries out early state programs in the areas of solid and liquid tumors. The company has partnership with various pharmaceutical companies to develop and commercialize anticancer compounds. ImmunoGen is headquartered in Waltham, Massachusetts, the US.

ImmunoGen Inc (IMGN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ImmunoGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

ImmunoGen Inc, Medical Devices Deals, 2012 to YTD 2018 10

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 12

ImmunoGen Enters into Research Agreement with Merck 13

Ventana Medical Systems Enters into Co-Development Agreement with ImmunoGen 14

CytomX Therapeutics Enters Into Co-Development Agreement With ImmunoGen fOR Probody-Drug Conjugates Therapies 15

Licensing Agreements 17

Takeda Enters into Licensing Agreement with ImmunoGen 17

CytomX Therapeutics Exercises Option for Licensing Agreement with ImmunoGen 18

ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 19

Equity Offering 20

ImmunoGen Raises USD150.7 Million in Public Offering of Shares 20

ImmunoGen Raises USD108.4 Million in Public Offering of Shares 22

ImmunoGen Plans to Raise up to USD50 Million in Public Offering 24

ImmunoGen Completes Public Offering Of Common Stock For USD 100 Million 25

Debt Offering 27

ImmunoGen Raises USD100 Million in Private Placement of 4.5% Notes Due 2021 27

Asset Transactions 28

Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 28

TPG Special Situations Partner to Acquire Kadcyla Royalty Rights from ImmunoGen for USD200 Million 29

ImmunoGen Inc-Key Competitors 30

ImmunoGen Inc-Key Employees 31

ImmunoGen Inc-Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 33

Financial Announcements 33

Nov 02, 2018: ImmunoGen reports recent progress and third quarter 2018 operating results 33

Jul 27, 2018: ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results 35

May 04, 2018: ImmunoGen Reports Recent Progress and First Quarter 2018 Operating Results 37

Feb 09, 2018: ImmunoGen Reports Pipeline Progress and 2017 Operating Results 39

Nov 03, 2017: ImmunoGen Reports Recent Progress and Third Quarter 2017 Operating Results 41

Jul 28, 2017: ImmunoGen Reports Recent Progress and Second Quarter 2017 Operating Results 43

May 05, 2017: ImmunoGen Reports Recent Progress and First Quarter 2017 Operating Results 45

Feb 17, 2017: ImmunoGen Reports Recent Progress and Operating Results for Six-Month Period and Quarter Ended December 31, 2016 47

Corporate Communications 49

Apr 25, 2018: ImmunoGen Appoints Blaine McKee as Executive Vice President and Chief Business Officer 49

Jan 23, 2017: ImmunoGen Announces Departure of Sandra Poole 50

Product News 51

03/14/2018: ImmunoGen Announces Presentations at AACR Annual Meeting Highlighting Continued Innovation in ADCs 51

Appendix 52

Methodology 52

About GlobalData 52

Contact Us 52

Disclaimer 52


List Of Figure

List of Figures

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

ImmunoGen Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

ImmunoGen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ImmunoGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ImmunoGen Inc, Deals By Therapy Area, 2012 to YTD 2018 9

ImmunoGen Inc, Medical Devices Deals, 2012 to YTD 2018 10

ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 12

ImmunoGen Enters into Research Agreement with Merck 13

Ventana Medical Systems Enters into Co-Development Agreement with ImmunoGen 14

CytomX Therapeutics Enters Into Co-Development Agreement With ImmunoGen fOR Probody-Drug Conjugates Therapies 15

Takeda Enters into Licensing Agreement with ImmunoGen 17

CytomX Therapeutics Exercises Option for Licensing Agreement with ImmunoGen 18

ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 19

ImmunoGen Raises USD150.7 Million in Public Offering of Shares 20

ImmunoGen Raises USD108.4 Million in Public Offering of Shares 22

ImmunoGen Plans to Raise up to USD50 Million in Public Offering 24

ImmunoGen Completes Public Offering Of Common Stock For USD 100 Million 25

ImmunoGen Raises USD100 Million in Private Placement of 4.5% Notes Due 2021 27

Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 28

TPG Special Situations Partner to Acquire Kadcyla Royalty Rights from ImmunoGen for USD200 Million 29

ImmunoGen Inc, Key Competitors 30

ImmunoGen Inc, Key Employees 31

ImmunoGen Inc, Subsidiaries 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

ImmunoGen Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.